Rosenbaum Jay D. lowered its stake in shares of Stryker Co. (NYSE:SYK) by 1.1% during the first quarter, HoldingsChannel reports. The institutional investor owned 11,124 shares of the medical technology company’s stock after selling 125 shares during the period. Stryker comprises about 4.2% of Rosenbaum Jay D.’s portfolio, making the stock its 3rd biggest position. Rosenbaum Jay D.’s holdings in Stryker were worth $2,196,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Oregon Public Employees Retirement Fund lifted its stake in shares of Stryker by 8,029.5% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 6,075,473 shares of the medical technology company’s stock valued at $39,000 after buying an additional 6,000,739 shares during the period. Norges Bank purchased a new position in shares of Stryker during the fourth quarter valued at approximately $474,132,000. BlackRock Inc. lifted its stake in shares of Stryker by 4.1% during the fourth quarter. BlackRock Inc. now owns 24,882,912 shares of the medical technology company’s stock valued at $3,900,399,000 after buying an additional 975,678 shares during the period. GQG Partners LLC purchased a new position in shares of Stryker during the fourth quarter valued at approximately $116,175,000. Finally, FMR LLC lifted its stake in shares of Stryker by 6.3% during the fourth quarter. FMR LLC now owns 5,934,622 shares of the medical technology company’s stock valued at $930,251,000 after buying an additional 353,028 shares during the period. 74.61% of the stock is currently owned by hedge funds and other institutional investors.

In other news, VP Michael Damon Hutchinson sold 10,109 shares of the stock in a transaction on Wednesday, February 6th. The shares were sold at an average price of $180.14, for a total value of $1,821,035.26. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP M Kathryn Fink sold 180 shares of the stock in a transaction on Monday, February 4th. The stock was sold at an average price of $176.77, for a total transaction of $31,818.60. The disclosure for this sale can be found here. Insiders have sold 130,455 shares of company stock valued at $24,723,292 in the last ninety days. 7.20% of the stock is currently owned by company insiders.

Several equities analysts recently issued reports on the stock. ValuEngine downgraded shares of Stryker from a “buy” rating to a “hold” rating in a research note on Thursday. Barclays upped their price objective on shares of Stryker from $203.00 to $211.00 and gave the company an “overweight” rating in a research note on Monday. Zacks Investment Research downgraded shares of Stryker from a “buy” rating to a “hold” rating in a research note on Friday, April 12th. Wells Fargo & Co upped their price objective on shares of Stryker from $214.00 to $219.00 and gave the company an “outperform” rating in a research note on Monday, April 1st. Finally, JPMorgan Chase & Co. upped their price objective on shares of Stryker from $200.00 to $215.00 and gave the company an “overweight” rating in a research note on Tuesday, March 19th. Nine investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $192.13.

Shares of SYK stock opened at $180.26 on Friday. Stryker Co. has a one year low of $144.75 and a one year high of $199.85. The company has a quick ratio of 1.41, a current ratio of 2.02 and a debt-to-equity ratio of 0.72. The company has a market cap of $67.26 billion, a P/E ratio of 24.66, a P/E/G ratio of 2.38 and a beta of 0.88.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Tuesday, January 29th. The medical technology company reported $2.18 EPS for the quarter, topping the consensus estimate of $2.15 by $0.03. Stryker had a net margin of 26.12% and a return on equity of 27.60%. The firm had revenue of $3.80 billion during the quarter, compared to analyst estimates of $3.73 billion. Research analysts anticipate that Stryker Co. will post 8.13 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, April 30th. Investors of record on Friday, March 29th will be given a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 1.15%. The ex-dividend date is Thursday, March 28th. Stryker’s dividend payout ratio (DPR) is 28.45%.

ILLEGAL ACTIVITY WARNING: “Stryker Co. (SYK) Position Reduced by Rosenbaum Jay D.” was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark laws. The original version of this story can be accessed at https://www.watchlistnews.com/stryker-co-syk-position-reduced-by-rosenbaum-jay-d/2974647.html.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

Further Reading: Do stock splits help investors?

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK).

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.